Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments.

ABSTRACT:

Background

Fecal microbiota transplantation (FMT) and fecal virome transplantation (FVT, sterile filtrated donor feces) have been effective in treating recurrent Clostridioides difficile infections, possibly through bacteriophage-mediated modulation of the gut microbiome. However, challenges like donor variability, costly screening, coupled with concerns over pathogen transfer (incl. eukaryotic viruses) with FMT or FVT hinder their wider clinical application in treating less acute diseases.

Methods

To overcome these challenges, we developed methods to broaden FVT's clinical application while maintaining efficacy and increasing safety. Specifically, we employed the following approaches: (1) chemostat-fermentation to reproduce the bacteriophage FVT donor component and remove e

SUBMITTER: Rasmussen TS 

PROVIDER: S-EPMC11218093 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature